Biegel & Waller’s Viridian Therapeutics VRDN Stock Holding History

Biegel & Waller’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$49K	Hold	4,434	–	–	0.03%	71
2019 Q2	$136K	Hold	4,434	–	–	0.07%	76
2019 Q1	$186K	Hold	4,434	–	–	0.1%	73
2018 Q4	$202K	Hold	4,434	–	–	0.12%	67
2018 Q3	$371K	Hold	4,434	–	–	0.21%	42
2018 Q2	$426K	Hold	4,434	–	–	0.27%	35
2018 Q1	$466K	Hold	4,434	–	–	0.3%	26
2017 Q4	$694K	Hold	4,434	–	–	0.4%	20
2017 Q3	$609K	Buy	+4,434	New	+$746K	0.38%	21

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Biegel & Waller's VRDN Position: Q3 2019 in Review

Biegel & Waller held its Viridian Therapeutics (VRDN) position steady in Q3 2019 at 4,434 shares worth $49K. The position accounts for 0.03% of the portfolio, ranked #71.

Biegel & Waller first reported a position in VRDN in Q3 2017 and has held it in 9 quarters since. The position peaked at $694K in Q4 2017. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

Biegel & Waller held 4,434 shares of Viridian Therapeutics worth $49K as of Q3 2019.
Biegel & Waller left its Viridian Therapeutics share count unchanged in Q3 2019.
Viridian Therapeutics made up 0.03% of Biegel & Waller's portfolio in Q3 2019, its #71 holding.
Biegel & Waller first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 9 quarters since.
Biegel & Waller's Viridian Therapeutics position peaked at $694K in Q4 2017.
33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Biegel & Waller's 13F filing for Q3 2019, filed 15 Oct 2019.